Abstract
An immunological profile has been serially studied in 72 patients with advanced breast cancer during the course of a randomized trial of chemotherapy and hormonal manipulation. DNCB+ patients were more likely to respond to either therapy, but no other test was predictive of response. In the follow-up period all chemotherapy patients had a reduction in white-cell count which was significantly greater in those responding to treatment. None of the other tests (phytohaemagglutinin response, immunoglobulins G, A and M, or Mantoux test) demonstrated changes that could be related to treatment or response, but there was a gradual unexplained fall in IgM levels in all groups the study progressed. It is concluded that the chemotherapeutic regimen (cyclophosphamide, vincristine, adriamycin and 5-fluorouracil) is relatively non-immunosuppressive, and that hormonal therapy (oophorectomy, tamoxifen or androgens) had no detectable effect on the immune response.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Edelstyn G. A., Macrae K. D. Cyclical combination chemotherapy in advanced breast cancer. Br J Cancer. 1973 Nov;28(5):459–461. doi: 10.1038/bjc.1973.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Franks C. R., Williams Y. The effect of sex hormones on peripheral immunity in patients with advanced breast cancer. Clin Oncol. 1978 Mar;4(1):19–24. [PubMed] [Google Scholar]
- Harris C. C. Immunosuppressive anticancer drugs in man: their oncogenic potential. Radiology. 1975 Jan;114(1):163–166. doi: 10.1148/114.1.163. [DOI] [PubMed] [Google Scholar]
- Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
- Mott M. G. Chemotherapeutic suppression of immune enhancement: a primary determinant of successful cancer therapy. Lancet. 1973 May 19;1(7812):1092–1094. doi: 10.1016/s0140-6736(73)90399-1. [DOI] [PubMed] [Google Scholar]
- O'Bryan R. M., Baker L. H., Gottlieb J. E., Rivkin S. E., Balcerzak S. P., Grumet G. N., Salmon S. E., Moon T. E., Hoogstraten B. Dose response evaluation of adriamycin in human neoplasia. Cancer. 1977 May;39(5):1940–1948. doi: 10.1002/1097-0142(197705)39:5<1940::aid-cncr2820390505>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
- Priestman T., Baum M., Jones V., Forbes J. Comparative trial of endocrine versus cytotoxic treatment in advanced breast cancer. Br Med J. 1977 May 14;1(6071):1248–1250. doi: 10.1136/bmj.1.6071.1248. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Whitehead R. H., Bolton P. M., Newcombe R. G., James S. L., Hughes L. E. Lymphocyte response to PHA in breast cancer: correlation of predicted prognosis to response to different PHA concentrations. Clin Oncol. 1975 Sep;1(3):191–200. [PubMed] [Google Scholar]
- Wilson R. E., Hager E. B., Hampers C. L., Corson J. M., Merrill J. P., Murray J. E. Immunologic rejection of human cancer transplanted with a renal allograft. N Engl J Med. 1968 Feb 29;278(9):479–483. doi: 10.1056/NEJM196802292780904. [DOI] [PubMed] [Google Scholar]
- Yonemoto R. H., Schick P., Albano W., Fujisawa T., Waldman S. H. Immune responses in the treatment of advanced carcinoma of the breast. Effects of adrenalectomy. Arch Surg. 1977 Aug;112(8):991–996. doi: 10.1001/archsurg.1977.01370080089015. [DOI] [PubMed] [Google Scholar]